Loading
Clene Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by MATLIN DAVID J, was filed 13 Jan 2026.
Clene Inc.: what insiders have been doing
Clene Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (19 October 2025 to 19 October 2026), 33 filings came from 4 insiders.
Open-market activity splits into 1 purchase totalling €186k and 26 sales totalling €2.1M; 1 insider sit on the buying side and 1 insider on the selling side. Taken together, the sales exceed the purchases by €1.9M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 senior executive among the declarants. Ugwumba Chidozie filed the largest sale, €382k, on 18 December 2025.
With 33 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. Our records for Clene Inc. go back to 2021, with 35 purchases and 43 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 200,000 USD and net income at -26.2 m USD.
The latest purchase dates back some time: it was published 279 days ago, on 13 January 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
101
Thresholds
n/a
Buy Volume
€20M
35 ops. · all time
Sell Volume
€3M
43 ops. · all time
Who traded when
BuySaleChidozie Ugwumba26 sales
General Resonance LLC8 sales
David J. Matlin1 buy
Since the insiders bought
- +30.5%Entry US$5.12 · Close at T+90 US$6.68
- +63.8%Entry US$4.89 · Close at T+365 US$8.01
- +63.8%Entry US$4.89 · Close at T+365 US$8.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.39
Analyst consensus
5 analysts1.20/5
US$20.00Target US$32.20(+850%)US$50.00
Income statement
RevenueUS$200k
Gross profitUS$157k79% margin
EBITDA-US$22M-10998% margin
Net income-US$26.2M-13086.5% margin
Valuation
PER (forward)-1.4x
Beta0.92
Balance sheet & cash
Market capUS$48.2M
Total debtUS$21.7M
Free Cash Flow-US$18.6M
Profitability & ownership
ROA-56.9%
% insiders16.5%
% institutions25.4%
Last declaration on 18 September 2026
Declarations101 total
198,171 shares@ US$3.281.05% mcap13.1% of flowcommon stockSEC:0001437749-26-030728:0
15,244 shares@ US$3.280.081% mcap15.0% of flowcommon stockSEC:0001437749-26-030729:0
434,451 shares@ US$3.282.31% mcap13.1% of flowcommon stockSEC:0001437749-26-030730:0
1,591 shares@ US$5.900.013% mcap0.1% of flowCommon StockSEC:0001835544-26-000017:0
12,170 shares@ US$5.630.096% mcap0.7% of flowCommon StockSEC:0001835544-26-000017:1
5,736 shares@ US$6.080.049% mcap0.3% of flowCommon StockSEC:0001835544-26-000017:2
4,318 shares@ US$6.120.049% mcap0.3% of flowCommon StockSEC:0001835544-26-000016:0
61,345 shares@ US$6.140.69% mcap3.7% of flowCommon StockSEC:0001835544-26-000016:1
6,374 shares@ US$6.480.076% mcap0.4% of flowCommon StockSEC:0001835544-26-000015:0
7,748 shares@ US$6.400.091% mcap0.5% of flowCommon StockSEC:0001835544-26-000015:1
25,040 shares@ US$6.430.30% mcap1.6% of flowCommon StockSEC:0001835544-26-000015:2
24,925 shares@ US$4.811.2% of flowCommon StockSEC:0001835544-26-000014:0
4,278 shares@ US$4.970.2% of flowCommon StockSEC:0001835544-26-000013:0
17,470 shares@ US$4.750.8% of flowCommon StockSEC:0001835544-26-000012:0
67,991 shares@ US$4.883.3% of flowCommon StockSEC:0001835544-26-000012:2
15,536 shares@ US$5.100.8% of flowCommon StockSEC:0001835544-26-000012:1
5,492 shares@ US$5.780.3% of flowCommon StockSEC:0001835544-26-000011:0
5,559 shares@ US$4.100.2% of flowCommon StockSEC:0001835544-26-000010:0
15,284 shares@ US$4.320.6% of flowCommon StockSEC:0001835544-26-000009:0
6,418 shares@ US$5.020.3% of flowCommon StockSEC:0001835544-26-000008:0
12,665 shares@ US$5.320.7% of flowCommon StockSEC:0001835544-26-000007:0
7,923 shares@ US$5.130.4% of flowCommon StockSEC:0001835544-26-000006:0
26,105 shares@ US$4.891.3% of flowCommon StockSEC:0001835544-26-000005:0
16,667 shares@ US$6.002.0% of flowCommon StockSEC:0001104659-26-003464:1
33,333 shares@ US$6.502.0% of flowcommon stockSEC:0001437749-26-001170:0
Canonical exit: 13 Apr 2026 (T+90)
25 of 101 declarations
About Clene Inc.
Clene Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq (CLNN) in the United States, with headquarters in Salt Lake City, Utah, and manufacturing plus R&D operations in Maryland. The company was founded in 2013 and has built its identity around a proprietary nanomedicine platform designed to restore neuronal health and function. For investors, Clene sits squarely in the neurodegenerative-disease innovation space, where the investment case is driven by clinical execution, regulatory progress, and financing capacity rather than near-term commercial scale. ([invest.clene.com](https://invest.clene.com/))
Clene’s lead asset is CNM-Au8®, an oral suspension of gold nanocrystals intended to improve cellular energy production and utilization by targeting mitochondrial function, the NAD pathway, and oxidative stress. The company is developing CNM-Au8 across several neurological indications, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease. In other words, Clene remains a development-stage biotech: its value proposition depends primarily on clinical data readouts, regulatory discussions, and the ability to raise capital, not on a mature product portfolio. ([invest.clene.com](https://invest.clene.com/news-releases/news-release-details/clene-reports-full-year-2025-financial-results-and-recent))
Read moreShow less
From a competitive standpoint, Clene is a niche player in a highly specialized segment of the biotech market. Its differentiation rests on a novel mechanism, a neuroprotective thesis, and the possibility of addressing diseases with substantial unmet medical need. That said, the company’s commercial position remains early and speculative, which is typical for small-cap U.S. biotech firms focused on central nervous system disorders. Management emphasizes scientific credibility and regulatory readiness, supported by executives with pharmaceutical, commercialization, and development experience. ([clene.com](https://clene.com/about/))
Recent developments have been particularly important. In March 2026, Clene said an in-person FDA Type C meeting was scheduled for the first quarter of 2026 to review the latest CNM-Au8 data, with the company targeting an ALS NDA submission under the accelerated approval pathway in the second quarter of 2026 if the interaction is positive. The company also disclosed an oversubscribed registered direct offering of more than $28 million in January 2026, followed by a $7 million underwritten offering announced in May 2026. Taken together, these updates show both progress toward a potential regulatory filing and the continuing importance of equity financing to sustain operations. For international investors, Clene is best viewed as a high-risk, catalyst-driven Nasdaq biotech in the United States, with upside tied to FDA milestones and clinical validation. ([invest.clene.com](https://invest.clene.com/news-releases/news-release-details/clene-reports-full-year-2025-financial-results-and-recent))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
